Cepheid Reports Fourth Quarter and Full Year 20...(withBroadlane a supply chain services co...)

Date:2/28/2008

with Broadlane, a supply chain services company serving more than 20,000 acute care hospitals, ambulatory care facilities, physician practices and other healthcare providers in the U.S. The agreement provides Broadlane customers with pre-negotiated pricing to take advantage of Cepheid's molecular diagnostic systems, reagents and services for its GeneXpert System and Xpert line of tests, including Xpert MRSA.

In January 2008, Cepheid began shipment of its next generation GeneXpert Systems and has added the single module GX-I System, for low-volume and portable system needs, to its family of GeneXpert System offerings. All systems now feature six-color optical capability that enables enhanced multiplex capabilities in a single cartridge. The systems also now feature software that enables Laboratory Information System (LIS) integration capabilities, linking any GeneXpert System to healthcare institutions' central database for receiving, processing and storing test results.

Cepheid is continuing to accelerate expansion of its U.S. sales and field service support organization based on the rapidly developing HAI market. In January, Cepheid completed training of personnel for 15 new positions within the sales organization. The sales organization is now comprised of 43 sales and field technical support positions in North America and 75 worldwide distributors. Cepheid plans to continue growing its sales and field technical support organization to scale with market demands for the GeneXpert System and its associated Xpert tests.

Outlook for 2008:

Cepheid financial guidance for the full year 2008:

-- Total revenues are expected to be in the range of $182 million to

$189 million

- Product sales are expected to be in the range of $175 million to

$180 million

- Other revenues are expected to be in the range of $7 million to

$9 million

-- Net income for 2008, exclud
'/>"/>

SOURCE Cepheid Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related biology technology :

1. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
2. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
3. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
4. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
5. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
6. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
7. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
8. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
9. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
10. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
11. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results